The suggestion [2015] that we were entering a new golden age for adjuvants was supported by the licensure in the US of several new vaccines which contained novel adjuvants, including AS01 (Shingrix), MF59 (Fluad) and immunostimulatory oligonucleotides (ISS 1018 in Heplisav). In addition, it ...